T-DXd improved PFS and response rates vs chemo in HR+/HER2-low or -ultralow metastatic breast cancer in DESTINY-Breast06.
HR Breast Cancer
Advertisement
Ribociclib plus ET shows similar pCR rates to chemo in intermediate-risk HR+/HER2– early breast cancer, per WSG ADAPTcycle.
PALMIRA trial shows limited benefit of palbociclib rechallenge in HR+/HER2- breast cancer, guiding future treatment choices.
Real-world data reveal varying efficacy of CDK4/6 inhibitors in HR+/HER2- aBC, supporting personalized treatment choices.
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Palbociclib rechallenge did not significantly improve PFS in HR+/HER2- advanced breast cancer, PALMIRA trial finds.
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.